Liftstream is an executive search recruitment company in the life sciences sector
MorphoSys based out of Munich and G7 Therapeutics AG of Zurich announced today that they have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors (GPCRs) and potentially other disease-related transmembrane proteins such as ion channels. Under the terms of the agreement, G7 Therapeutics will generate a set of disease-relevant receptors proposed by MorphoSys. MorphoSys will then apply its proprietary Ylanthia antibody library to discover and develop antibody therapeutics against these receptors. MorphoSys has the right to sublicense to third parties the access to these targets in conjunction with therapeutic antibody candidates.Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG, commented: “G7 Therapeutics’ approach using directed evolution technologies broadens our existing development capabilities in this innovative area of research. High quality therapeutic antibodies targeting GPCRs and other transmembrane molecules represent a promising addition to our proprietary development pipeline.”
Xencor, Inc., a clinical-stage biopharmaceutical company based in California which is developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, have appointment Yujiro S. Hata to its board of directors.
Oncology drug development is one of the largest areas within the pharmaceutical industry, addressing a disease area that causes more deaths than all other diseases apart from cardiovascular. The current global oncology market is estimated to be in the region of $55bn and forecast to grow to over $70bn by 2016. The oncology market is often seen as the most diverse with a wide range of indications and there are some 900 estimated clinical programmes currently underway. It is estimated that there are more than 200 different forms of cancer and therefore the oncology market presents a unique set of challenges to the industry.